- Home
- ANVS vs IFRX Comparison
ANVS vs IFRX Comparison
Compare ANVS & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANVS | IFRX |
|---|---|---|
| Founded | 2008 | 2007 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 111.3M | 60.6M |
| IPO Year | 2019 | 2017 |
Fundamental Metrics
Financial Performance| Metric | ANVS | IFRX |
|---|---|---|
| Price | $2.50 | $0.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $13.50 | $8.50 |
| AVG Volume (30 Days) | ★ 314.3K | 171.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.92 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,054.36 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.11 | $0.71 |
| 52 Week High | $5.50 | $1.94 |
Technical Indicators
Market Signals| Indicator | ANVS | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 43.98 | 52.69 |
| Support Level | $2.27 | $0.75 |
| Resistance Level | $2.63 | $1.16 |
| Average True Range (ATR) | 0.20 | 0.07 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 17.64 | 50.85 |
Price Performance
Historical ComparisonAbout ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.